Lineage Cell Therapeutics Inc LCTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
-
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
-
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
Trading Information
- Previous Close Price
- $0.93
- Day Range
- $0.91–0.96
- 52-Week Range
- $0.88–2.09
- Bid/Ask
- $0.97 / $0.98
- Shares Outstanding
- 252.91M
- Market Cap
- $234.55M
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 17.58
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 77
- Website
- https://www.lineagecell.com
Valuation
|
Metric
|
LCTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.86 |
Price/Sales | 17.58 |
Price/Cash Flow | — |
Price/Earnings
LCTX
Financial Strength
|
Metric
|
LCTX
|
|---|---|
Quick Ratio | 6.44 |
Current Ratio | 6.61 |
Interest Coverage | — |
Quick Ratio
LCTX
Profitability
|
Metric
|
LCTX
|
|---|---|
Return on Assets (Normalized) | −14.86% |
Return on Equity (Normalized) | −32.90% |
Return on Invested Capital (Normalized) | −35.36% |
Return on Assets
LCTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<<KrD? | LOCK|#XXt | $128B | |||
| Moderna Inc
MRNA
| LOCK|%p>H&>q | LOCK|gX | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|CzGj%H> | LOCK|TKlcG | $76B | |||
| argenx SE ADR
ARGX
| LOCK|HPq>>f | LOCK|^L | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?#z%FV | LOCK|%VP | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|bN!wY<V | LOCK|%!Cq^ | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%H&!FSz | LOCK|prM## | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|@$wcs@ | LOCK|@mX | $24B | |||
| Incyte Corp
INCY
| LOCK|^??nk&< | LOCK|!q | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|k@T$Fw | LOCK|Jk& | $15B |
United States